Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 76 results for "qmg"

Huntington Theatre Company to Remain at Present Location
Boston University

Huntington Theatre Company to Remain at Boston University Theatre

Mayor Martin J. Walsh joined Huntington Managing Director Michael Maso and developer John Matteson of QMG Huntington, LLC to announce a partnership that will allow the Huntington Theatre Company to stay in its current home, the Boston University ... Broadway World, 2 weeks ago

1 images for "qmg"

XinMsn, 2 months ago
Share Market Updates

HC Stocks to watch for: Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN), CVS Health Corp (NYSE:CVS)

Shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN ) ended Friday session in red amid volatile trading. The shares closed down -10.58 points or -8.56 % at $ 112.99 with 7.51 million shares getting traded. Post opening the session at $ 117.50 , the ...
 Share Market Updates18 hours ago HC Stocks Outlines: Relypsa Inc (NASDAQ:RLYP), Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN)  Share Market Updates4 days ago

Pope's visit to Armenia a message of peace to the South Caucasus still suffering from Azeri provocations

Pope's visit to Armenia a message of peace to the South Caucasus still suffering from Azeri provocations 22:35, 20 Jun 2016 Siranush Ghazanchyan The Pope's visit to Armenia will bring a message of peace to the whole region of South Caucasus still ...
 Groong1 week ago

Alexion Announces Topline Results from Phase 3 REGAIN Study of Eculizumab Soliris in Patients with Refractory Generalized Myasthenia Gravis gMG

By a News Reporter-Staff News Editor at Clinical Trials Week Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) announced topline results from the REGAIN study, a Phase 3 registration trial of eculizumab (Soliris) in patients with refractory generalized ...
 Pharmacy Choice1 week ago Alexion's phase 3 study of eculizumab in refractory gMG fails to meet primary goal  Pharmaceutical Business Review2 weeks ago ALEXION PHARMACEUTICALS : Announces Topline Results from Phase 3 REGAIN Study of Eculizumab (SolirisĀ®) in Patients with Refractory Generalized Myasthenia Gravis (gMG)  4 Traders3 weeks ago

Little League All-Stars tournaments to begin

Little League All-Star baseball teams from Chino, Chino Hills, Ontario, Upland and Montclair will begin play for District 23 championships Saturday, June 25 in the 8-9-10, 9-10-11, Major and Junior divisions. Games in the Senior Division begin ...
 Champion Newspapers1 week ago
Melbourne Age

Technically, the ASX could fall to 5000

The S&P/ASX200 index could fall as low as 5000 points if negative momentum continues, according to an analysis of technical levels. The benchmark was trading around 5190 on Wednesday afternoon, down 0.4 per cent from Tuesday's close of 5203.2. The ...
 Melbourne Age1 week ago

Here are NASA's Retro Mars Recruitment Posters Everyone is Talking About

NASA says it will eventually send people to Mars. With that, the agency released a series of Mars Explorer Wanted posters which can be downloaded and reproduced for free for non-commercial use. (Photo : Jasin Boland/Warner Bros./Newsmakers) ...
 NatureWorldNews.com1 week ago

Shares could tumble back through 5000 barrier, charts suggest

The Australian sharemarket has shed around four per cent since reaching 5,400 points in late May 2016, and technical analysis suggests that the S&P/ASX 200 could test the 5,000-point level. Angela Mangan of QMG says 5,300 was the benchmark index's ...
 TradingCharts.com1 week ago
Dime Magazine

NJPW Crowned The Winner Of The 2016 Best Of The Super Juniors Tournament

NJPW World So, remember how Ricochet and Will Ospreay accidentally lit the internet on fire with their match for New Japan Pro Wrestling ? I certainly hope you took the opportunity to watch it while it was posted for free on New Japan World and ...
 Dime Magazine2 weeks ago

Regain Pain For Alexion's Soliris

Alexion's (NASDAQ: ALXN ) efforts to expand the indications for its orphan disease drug Soliris have taken a blow after a phase III trial in myasthenia gravis failed to meet its primary endpoint. The company seems determined to persevere in the ...
 Seeking Alpha2 weeks ago Alexion's Soliris fails in late-stage myasthenia gravis trial  BioPharma Dive2 weeks ago Alexion's Soliris flunks late-stage study in ultra-rare type of myasthenia gravis; shares off 9% after hours  Seeking Alpha3 weeks ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Get updated on latest news & your favorite topics right in your inbox!
More     Less